A Weight Loss drug described as a game-changer by the obesity researchers has just been approved by the US Food and Drug Administration, representing the first time the agency has endorsed such a treatment in several years. Wegovy, a weight-management therapy to be manufactured by Danish pharmaceutical company Novo Nordisk, is the first FDA-approved weight-loss drug since 2014.
The same drug, called semaglutide, has been used in the US and other countries as an anti-diabetic medication for years. The evidence has shown that semaglutide at a different dosage also functions as a powerful and effective appetite-suppressant.
The agency announced that semaglutide had been approved for chronic weight management in adults who are either obese or overweight, and who have at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. The therapy, which is expected to be launched by Novo Nordisk in the US later this month, comes in the form of a once-weekly injection, delivering the hormone glucagon-like peptide-1 that makes recipients feel fuller, helping them to subsequently eat less.